AVITA Medical, Inc.

NasdaqCM:RCEL Stok Raporu

Piyasa değeri: US$350.2m

AVITA Medical Yönetim

Yönetim kriter kontrolleri 2/4

AVITA Medical CEO'su Jim Corbett, Sep2022 tarihinde atandı, in görev süresi 2.17 yıldır. in toplam yıllık tazminatı $ 2.07M olup, şirket hissesi ve opsiyonları dahil olmak üzere 30.2% maaş ve 69.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.033% ine doğrudan sahiptir ve bu hisseler $ 116.01K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 6.1 yıldır.

Anahtar bilgiler

Jim Corbett

İcra Kurulu Başkanı

US$2.1m

Toplam tazminat

CEO maaş yüzdesi30.2%
CEO görev süresi2.2yrs
CEO sahipliği0.03%
Yönetim ortalama görev süresi1.8yrs
Yönetim Kurulu ortalama görev süresi6.1yrs

Son yönetim güncellemeleri

Recent updates

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Oct 04
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jul 18
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18
Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

Apr 12
Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

Feb 02
AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Oct 20
The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Avita Medical appoints James Corbett as CEO

Sep 29

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

Sep 12

Avita's burn therapy Recell gets insurance coverage in Japan following approval

Sep 01

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

Aug 11

AVITA Medical Is Interesting, But Not Just Yet

Dec 21

AVITA Medical reports preliminary Q2 revenue in-line with consensus

Jan 12

AVITA: COVID-19's Impact

Nov 17

CEO Tazminat Analizi

Jim Corbett'un ücretlendirmesi AVITA Medical'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$57m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$2mUS$625k

-US$35m

Sep 30 2023n/an/a

-US$34m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$2mUS$157k

-US$27m

Sep 30 2022n/an/a

-US$30m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$256kn/a

-US$25m

Tazminat ve Piyasa: Jim 'ın toplam tazminatı ($USD 2.07M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.14M ).

Tazminat ve Kazançlar: Jim şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jim Corbett (66 yo)

2.2yrs

Görev süresi

US$2,068,675

Tazminat

Mr. James M. Corbett, also known as Jim, served as Chief Executive Officer of CathWorks Ltd. since October 27, 2017 until 2021. He serves as Director of CathWorks Ltd.until 2021. He served as an Independe...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
James Corbett
CEO, President & Executive Director2.2yrsUS$2.07m0.033%
$ 116.0k
David O'Toole
Chief Financial Officer1.4yrsUS$2.18mVeri yok
David Fencil
Senior Vice President of Global Operations1.8yrsVeri yokVeri yok
Katie Bush
Senior Vice President of Scientific & Medical Affairsless than a yearVeri yokVeri yok
Jessica Ekeberg
Investor Relations Executiveno dataVeri yokVeri yok
Nicole Kelsey
Chief Legal & Compliance Officer and Corporate Secretaryless than a yearVeri yokVeri yok
Debbie Garner
Senior Vice President of Global Marketing & Strategy6.3yrsVeri yokVeri yok
Rob Hall
Senior Vice President of Human Resources1.8yrsVeri yokVeri yok
Niraj Doshi
Senior Vice President of Product Development & Program Management1.8yrsVeri yokVeri yok
Ron Lagerquist
Senior Vice President of Quality Assurance & Regulatory Affairs1.8yrsVeri yokVeri yok
Robin VanDenburgh
Senior Vice President of U.S. Commercial Salesless than a yearVeri yokVeri yok

1.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: RCEL 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
James Corbett
CEO, President & Executive Director3.3yrsUS$2.07m0.033%
$ 116.0k
Jan Reed
Independent Non-Executive Director3.3yrsUS$211.12k0.11%
$ 385.8k
Jeremy Curnock-Cook
Independent Non-Executive Director12.1yrsUS$199.87k0.079%
$ 275.2k
Fiona Wood
Founder and Member of Clinical Advisory Board8.8yrsUS$29.80kVeri yok
Louis Panaccio
Independent Non-Executive Chairman10.3yrsUS$234.69k0.16%
$ 576.4k
Robert McNamara
Independent Non-Executive Director1.6yrsUS$369.11k0.075%
$ 262.1k
Cary Vance
Independent Non-Executive Director1.6yrsUS$364.94k0.037%
$ 128.6k
Suzanne Crowe
Independent Non-Executive Director8.8yrsUS$195.28k0.10%
$ 363.5k

6.1yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RCEL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).